Proactive research analyst John Savin speaks to Thomas Warner at the London studio after releasing his latest report into commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF).
Savin says that Shield Therapeutics is "in fast growth mode" after its first full year of trading and gives his take on how he expects the company to perform in 2023.